MBRX Quote, Financials, Valuation and Earnings

Harvard Bioscience, Inc. has a net margin of -- compared to Moleculin Biotech, Inc.'s net margin of -5.98%. Moleculin Biotech, Inc.'s return on equity of -552.21% beat Harvard Bioscience, Inc.'s return on equity of -155.33%.

Moleculin Biotech, Inc. has a consensus price target of $6.67, signalling upside risk potential of 2202.03%. On the other hand Harvard Bioscience, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 163.96%. Given that Moleculin Biotech, Inc. has higher upside potential than Harvard Bioscience, Inc., analysts believe Moleculin Biotech, Inc. is more attractive than Harvard Bioscience, Inc..

Moleculin Biotech, Inc. has a beta of 1.582, which suggesting that the stock is 58.192% more volatile than S&P 500. In comparison Harvard Bioscience, Inc. has a beta of 1.531, suggesting its more volatile than the S&P 500 by 53.123%.

Moleculin Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harvard Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Moleculin Biotech, Inc. pays -- of its earnings as a dividend. Harvard Bioscience, Inc. pays out -- of its earnings as a dividend.

Moleculin Biotech, Inc. quarterly revenues are --, which are smaller than Harvard Bioscience, Inc. quarterly revenues of $20.6M. Moleculin Biotech, Inc.'s net income of -$25.4M is lower than Harvard Bioscience, Inc.'s net income of -$1.2M. Notably, Moleculin Biotech, Inc.'s price-to-earnings ratio is -- while Harvard Bioscience, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moleculin Biotech, Inc. is -- versus 0.38x for Harvard Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Intensity Therapeutics, Inc. has a net margin of -- compared to Moleculin Biotech, Inc.'s net margin of --. Moleculin Biotech, Inc.'s return on equity of -552.21% beat Intensity Therapeutics, Inc.'s return on equity of -380.13%.

Moleculin Biotech, Inc. has a consensus price target of $6.67, signalling upside risk potential of 2202.03%. On the other hand Intensity Therapeutics, Inc. has an analysts' consensus of $2.92 which suggests that it could grow by 471.9%. Given that Moleculin Biotech, Inc. has higher upside potential than Intensity Therapeutics, Inc., analysts believe Moleculin Biotech, Inc. is more attractive than Intensity Therapeutics, Inc..

Moleculin Biotech, Inc. has a beta of 1.582, which suggesting that the stock is 58.192% more volatile than S&P 500. In comparison Intensity Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Moleculin Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intensity Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Moleculin Biotech, Inc. pays -- of its earnings as a dividend. Intensity Therapeutics, Inc. pays out -- of its earnings as a dividend.

Moleculin Biotech, Inc. quarterly revenues are --, which are smaller than Intensity Therapeutics, Inc. quarterly revenues of --. Moleculin Biotech, Inc.'s net income of -$25.4M is lower than Intensity Therapeutics, Inc.'s net income of -$2.7M. Notably, Moleculin Biotech, Inc.'s price-to-earnings ratio is -- while Intensity Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moleculin Biotech, Inc. is -- versus -- for Intensity Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Moleculin Biotech, Inc.'s net margin of -255.85%. Moleculin Biotech, Inc.'s return on equity of -552.21% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Moleculin Biotech, Inc. has a consensus price target of $6.67, signalling upside risk potential of 2202.03%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -29.75%. Given that Moleculin Biotech, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Moleculin Biotech, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Moleculin Biotech, Inc. has a beta of 1.582, which suggesting that the stock is 58.192% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Moleculin Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Moleculin Biotech, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Moleculin Biotech, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Moleculin Biotech, Inc.'s net income of -$25.4M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Moleculin Biotech, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 2.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moleculin Biotech, Inc. is -- versus 2.35x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Moleculin Biotech, Inc.'s net margin of --. Moleculin Biotech, Inc.'s return on equity of -552.21% beat Palatin Technologies's return on equity of --.

Moleculin Biotech, Inc. has a consensus price target of $6.67, signalling upside risk potential of 2202.03%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Moleculin Biotech, Inc., analysts believe Palatin Technologies is more attractive than Moleculin Biotech, Inc..

Moleculin Biotech, Inc. has a beta of 1.582, which suggesting that the stock is 58.192% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Moleculin Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Moleculin Biotech, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Moleculin Biotech, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Moleculin Biotech, Inc.'s net income of -$25.4M is higher than Palatin Technologies's net income of --. Notably, Moleculin Biotech, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moleculin Biotech, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.